Annovis Bio Files Patent Application for Method of Inhibiting, Preventing, or Treating Neurological Injuries Due to Viral and Other Infections…

BERWYN, Pa., May 27, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimers disease (AD), Parkinsons disease (PD) and other neurodegenerative diseases, announced todaythat it filed a patent application with the U.S. Patent & Trademark Office (USPTO) concerning a method of inhibiting, preventing, or treating neurological injuries due to viral, bacterial, fungal, protozoan, or parasitic infections in humans and in animals via administration of ANVS401 or related compounds.

Researchers have noted the similarities between many types of infections of the brain, including infections resulting from COVID-19, commented Maria Maccecchini, Ph.D., CEO of Annovis Bio. In fact, autopsies conducted in China have shown the coronavirus to be present in the brain and some people infected with the virus have developed encephalitis and other neurological problems. In addition to our own studies, a number of universities and companies are looking at how viral and bacterial infections (e.g., herpes, HIV, Zika, Lyme disease, gingivitis) cause neurological disorders and neurodegeneration. These short- and long-term neurological problems arecaused becauseinvasion of the brain by a virus or bacterium causes levels of neurotoxic proteins to rise, which consequently impairs axonal transport, induces inflammation, and leads to nerve cell death. Because ANVS401 has been shown to protect nerve cells against the ill effects of an increase of neurotoxic proteins in the brain, we believe our compound could help with the treatment of neurological diseases associated with COVID-19 and other infections.

A brain infection is a bacterial, viral, fungal, protozoan, or parasitic infection of the tissue of the brain itself or the membranes surrounding the brain andspinal cord. Bacteria andvirusesare the most common causes of brain infections.

About Annovis Bio

Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimers disease (AD), Parkinsons disease (PD) and Alzheimers in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have an ongoing Phase 2a study in AD patients and plan to commence a second Phase 2a study in PD patients and AD patients. For more information on Annovis, please visit the companys website:www.annovisbio.com.

Forward-Looking Statements

Statements in this press release contain forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as anticipate, expect, believe, will, may, should, estimate, project, outlook, forecast or other similar words, and include, without limitation, statements regarding the timing, effectiveness and anticipated results of ANVS401 clinical trials. Forward-looking statements are based on Annovis Bio, Inc.s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Such risks include the possibility that the patent application referenced in this release may not be approved, the timing of any decision by the USPTO, and that ANVS401 is subject to further clinical trials and may not be an effective treatment of infections. These and other risks and uncertainties are described more fully in the section titled Risk Factors in the Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.

Investor Relations:

Dave Gentry, CEORedChip Companies Inc.407-491-4498Dave@redchip.com

SOURCE: Annovis Bio Inc.

See the original post here:
Annovis Bio Files Patent Application for Method of Inhibiting, Preventing, or Treating Neurological Injuries Due to Viral and Other Infections...

Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology – Yahoo Finance

MELBOURNE, Austriliaand SAN FRANCISCO, May 21, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has presented data on ATH434 (formerly PBT434) for the treatment of Multiple System Atrophy at the American Academy of Neurology (AAN) virtual meeting.

Chief Medical Officer & Senior VP Clinical Development, Dr David Stamler had been invited to make an oral presentation at the Parkinson's Disease Interventions and Clinical Trials session at the AAN Annual meeting in Toronto in April 2020 but the meeting was cancelled due to the COVID-19 pandemic. This was replaced with the opportunity to make a virtual presentation which is currently live on the 2020 AAN Science Highlights Virtual Platform available here.

The presentation was based on an abstract entitled A Phase 1 Study of PBT434, a Novel Small Molecule Inhibitor of a-Synuclein Aggregation, in Adult and Older Adult Volunteers published in the journal Neurology.

In addition, Dr Stamler was interviewed by Neurology Today. The article is available here.

The abstract, presentation and article share findings from Alterity's completed Phase 1 trial of leading drug candidate ATH434, which evaluated the safety, tolerability, and pharmacokinetics in healthy adult and older adult volunteers.

Importantly, the abstract provides detailed data demonstrating that ATH434 not only crosses the blood brain barrier in humans, but that clinically tested doses achieved concentrations in the brain that were comparable to or exceeded those associated with efficacy in animal models of disease. Safety data were presented indicating that ATH434 was well tolerated and demonstrated a similar adverse event profile in adults and older ( 65 years) adults.

The data support Alterity's plans to proceed with clinical testing of ATH434 for the treatment of Multiple System Atrophy, a form of atypical Parkinsonism.

Dr David Stamler told Neurology Today: "Because we're treating the underlying cause of disease by targeting alpha synuclein, I think we have potential to affect all aspects of disease the motor symptoms, the blood pressure problems, gait and balance, and even bowel and bladder dysfunction."

END

Authorisation & Additional informationThis announcement was authorised by Geoffrey Kempler, CEO and Chairman of Alterity Therapeutics Limited.

Contact:

Investor RelationsRebecca Wilson, WE CommunicationsE: WE-AUAlterity@we-worldwide.com Tp: +61 3 8866 1216

View original content:http://www.prnewswire.com/news-releases/alterity-therapeutics-presents-data-on-ath434-to-the-american-academy-of-neurology-301063273.html

SOURCE Alterity Therapeutics Limited

Go here to see the original:
Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology - Yahoo Finance

Enteral Feeding Device Used for Neurology Market to 2025: Growth Analysis by Manufacturers, Regions, Types and Applications – 3rd Watch News

A recent research on Enteral Feeding Device Used for Neurology market, now available with Market Study Report, LLC, is a thorough study on the latest market trends prevailing in the global business sphere. The report also offers important details pertaining to market share, market size, profit estimations, applications and statistics of this industry. The report further presents a detailed competitive analysis including growth strategies adopted by key players of the industry.

.

Request a sample Report of Enteral Feeding Device Used for Neurology Market at:https://www.marketstudyreport.com/request-a-sample/2701282?utm_source=3wnews.org/&utm_medium=VSD

The recent document on the Enteral Feeding Device Used for Neurology market involves breakdown of this industry as well as division of this vertical. As per the report, the Enteral Feeding Device Used for Neurology market is subjected to grow and gain returns over the predicted time period with an outstanding growth rate y-o-y over the predicted period.

As per the study, information regarding valuable estimation of the Enteral Feeding Device Used for Neurology market related to the sales capacity, profit projections, market size and other crucial parameters are present. Data regarding the industry segmentation along with the driving forces impacting the enumeration scale of this industry is included in the report.

Enumerating the Enteral Feeding Device Used for Neurology market with regards to the geographical landscape

Ask for Discount on Enteral Feeding Device Used for Neurology Market Report at:https://www.marketstudyreport.com/check-for-discount/2701282?utm_source=3wnews.org/&utm_medium=VSD

An outline of important points of the Enteral Feeding Device Used for Neurology market report

The Enteral Feeding Device Used for Neurology market report states that the industry is presumed to account a significant revenue over the predicted time period. It consists of data concerning the market dynamics such as challenges, growth opportunities along with the issues affecting the business domain.

For More Details On this Report:https://www.marketstudyreport.com/reports/global-enteral-feeding-device-used-for-neurology-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: Enteral Feeding Device Used for Neurology Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

Chapter 4: Enteral Feeding Device Used for Neurology Market, By Region

Chapter 5: Company Profile

Business Overview

Financial Data

Product Landscape

Strategic Outlook

SWOT Analysis

Related Reports:

1. Global Medical Enteral Feeding Bags Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025The Medical Enteral Feeding Bags Market Report offer the complete scenario of the industry and valuation of upcoming Trends for future market. It also gives the analytic of enduring growth factor, trends and statistic of Medical Enteral Feeding Bags Market industry. The Medical Enteral Feeding Bags Market has been outlined by overall information and analysis.Read More: https://www.marketstudyreport.com/reports/global-medical-enteral-feeding-bags-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

2. Global Medical Tube Feed Pumps Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025Medical Tube Feed Pumps Market report starts from illustration of Industry Chain structure, and portrays industry condition, at that point investigations advertise size and figure of Medical Tube Feed Pumps by item, district and application, likewise, this report presents showcase rivalry circumstance among the merchants profile, plus, advertise value examination and esteem chain highlights are canvassed in this report.Read More: https://www.marketstudyreport.com/reports/global-medical-tube-feed-pumps-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

Related Report : https://www.marketwatch.com/press-release/by-2026-4d-printing-market-size-revenue-to-reach-usd-4195-million-2020-06-10

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Visit link:
Enteral Feeding Device Used for Neurology Market to 2025: Growth Analysis by Manufacturers, Regions, Types and Applications - 3rd Watch News

Ipsen: New Surveys Show Over 80% of Patients with Spasticity and Cervical Dystonia Treated with Botulinum Toxin-A Experience Debilitating Symptom…

PARIS--(BUSINESS WIRE)--Regulatory News:

Ipsen (Euronext: IPN; ADR: IPSEY) today presents the results of two patient surveys. The surveys involved over 400 respondents from five countries, living with spasticity or cervical dystonia and receiving botulinum neurotoxin type A (BoNT-A) injections. The results show that over 80% of respondents experienced debilitating symptom recurrence, and revealed that a lack of long-lasting symptom control between injections has a profound impact on the personal and professional lives of patients.1-4

The results from these two important patient surveys provide significant insight into the real-life burden of the two conditions; however, they also highlight a worrying disconnect between patients treatment expectations and their actual experience. The findings, which build on our growing understanding of spasticity and cervical dystonia, provide us with the potential to unlock meaningful changes in clinical practice, said Dr Alberto Esquenazi, Department of Physical Medicine and Rehabilitation, Gait and Motion Analysis Laboratory, MossRehab and Albert Einstein Medical Centre, U.S. and lead investigator on the spasticity survey.

The first survey1,2 investigated the burden of spasticity on patients lives. Of the 210 respondents from France, Germany, Italy, the U.K., and the U.S., 83% reported that symptoms of spasticity returned between two sessions of BoNT-A, with 59% of these patients experiencing that return within three months of their last treatment. Symptom recurrence significantly impacted patients quality of life, including sleep, relationships, performance of daily tasks and working lives. In addition, 47% of working patients reported being unable to work when symptoms re-emerge and 45% of working patients felt less efficient at work than before.1,2

The second survey3,4 adopted a similar approach, analyzing data from 209 respondents with cervical dystonia from across France, Germany, Italy, the U.K., and the U.S. Of the respondents, 88% reported the reappearance of pre-existing symptoms between BoNT-A injections. The majority of working respondents reported a significant impact on their professional life, with 66% stating that they did not feel comfortable at work and 66% did not feel as efficient at work as usual. Patients personal lives were also significantly compromised by their symptom recurrence, with an impact on their ability to socialize, sleep well, drive, or perform daily tasks.3,4

In both surveys, over 70% of patients said they would like longer lasting benefits from their treatment.1-4

The Carenity 2 surveys reveal the debilitating impact that symptom recurrence can have across every aspect of life for patients with spasticity and cervical dystonia, indicating that more needs to be done to relieve the burden of symptoms for patients suffering from these neurological conditions.1-4

Full results of the Carenity 2 survey in spasticity were published in Frontiers in Neurology on 07 May 2020.1

Antony Fulford-Smith, Vice President, Global Medical Affairs, Ipsen, commented: Spasticity and cervical dystonia have a devastating effect on patients lives, seriously affecting their mobility, employment and quality of life. At Ipsen, we are constantly searching for ways to improve disease management and comprehensive care with a patient-centered approach. Its clear from these surveys that more can be done to relieve the burden of these challenging diseases on patients day-to-day lives.

Spasticity and cervical dystonia are distinct neurological conditions, though they share the characteristics of poor muscle control and spasms and are routinely treated with BoNT-A injections.3,5,6 Spasticity affects more than 12 million people worldwide7 and is generally caused by damage to the area of the brain and spinal cord responsible for controlling muscle and stretch reflexes due to stroke, traumatic brain and spinal cord injury, multiple sclerosis and cerebral palsy.5 Cervical dystonia is a rare disorder of unknown origin in most of the primary cases, characterized by involuntary contractions of the neck muscles.6

About the Carenity 2 surveys

The two patient surveys, commissioned by Ipsen, were conducted between May to September 2019 by Carenity, an online patient community. A total of 419 respondents from France, Germany, Italy, the U.K and the U.S responded to the surveys via the online platform Carenity. Eligible participants were over 18 years old and had (or cared for someone with) spasticity or cervical dystonia (CD) treated with BoNT-A for at least one year. To assess burden of spasticity or CD for patients and their caregivers, the Carenity 2 surveys explored the impact of symptom re-emergence on quality of life.1-4

Ipsen has an ongoing partnership with Carenity, a social media platform for people living with chronic diseases and presented findings from the first Carenity international survey which focused on spasticity at TOXINS 2019.8

About spasticity

Spasticity is estimated to affect more than 12 million people worldwide.7 It is a condition in which certain muscles are continuously contracted causing stiffness or tightness of the muscles, which can interfere with normal movement, gait and speech.5 Spasticity is usually caused by damage to the parts of the brain or spinal cord that control voluntary movement,5,9 leading to a change in the balance of signals between the nervous system and the muscles which leads to increased activity in the muscles.5 Spinal cord injury, multiple sclerosis, cerebral palsy, stroke, brain or head trauma and metabolic diseases can all cause spasticity.9 Spasticity is experienced by 34% of stroke survivors within 18 months following a stroke.10

About cervical dystonia

Cervical dystonia (CD), also known as spasmodic torticollis, is a movement disorder in which involuntary muscular contractions occur primarily in the neck muscles.6,11 This can cause the head to turn to one side or to be pulled backward or forward.6,12 CD is relatively uncommon, affecting 57 to 280 people per million.13 It can occur at any age, although symptoms generally appear in middle age, often beginning slowly and usually reaching a plateau over a few months or years.14 The degeneration of the spine, irritation of nerve roots or frequent headaches can make CD particularly painful.14 In most cases the cause is unknown and no cure exists.13

About Ipsen

Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. The Group develops and commercializes innovative medicines in three key therapeutic areas Oncology, Neuroscience and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over 2.5 billion in 2019, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsens R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,800 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit http://www.ipsen.com.

IpsenCautionary Note Regarding Forward-Looking Statements

The forward-looking statements, objectives and targets contained herein are based on the Groups management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Groups future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words "believes", "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements, including the Groups expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons and also taking into consideration assessment delays of certain clinical trials in light of the ongoing COVID-19 pandemic. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Groups patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Groups activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Groups partners could generate lower revenues than expected. Such situations could have a negative impact on the Groups business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Groups business is subject to the risk factors outlined in its registration documents filed with the French Autorit des Marchs Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Groups 2018 Registration Document available on its website (www.ipsen.com).

References

See the article here:
Ipsen: New Surveys Show Over 80% of Patients with Spasticity and Cervical Dystonia Treated with Botulinum Toxin-A Experience Debilitating Symptom...

Novartis study reveals that migraine support in the workspace can significantly decrease the impact of the disease on affected employees -…

Basel, May 26, 2020 Novartis announces data from its Migraine Care pilot program which was created in collaboration with patient groups and leading experts in neurology, telemedicine and digital medicine, to provide a complementary, independent, third-party service for all Swiss-based Novartis associates living with migraine to improve their quality of life. These data have been published in the European Journal of Neurology after the 6th Congress of the European Academy of Neurology was held virtually due to COVID-19.

The study confirms the high burden of people living and working with migraine but also demonstrates that empowering individuals can significantly increase quality of life and productivity, said Dr. Gantenbein, Head of the Swiss Headache Society. This further emphasizes the notion that employer-led well-being programs can benefit individuals, companies and society as a whole.

About Migraine Care

Migraine Care is a pilot program created by Novartis, in collaboration with patient groups and leading experts in neurology, telemedicine and digital medicine, to provide a complementary, independent, third-party service for all Swiss-based Novartis associates living with migraine to improve their quality of life. The program, endorsed by the Swiss Headache Society, aims to raise awareness of migraine in the workplace and provide free coaching to Novartis associates living with migraine. It also aims to empower associates in the management of the disease by leveraging both medical and lifestyle options.

339 Novartis employees registered to the program, out of which 141 consented to their data being analyzed and 79 completed the program at six months. Participants received monthly sessions of individualized telecoaching comprised of educational modules and action plans from a specialized nurse by phone and through a specially developed module on the Migraine Buddy smartphone application. The mean age of participants at baseline was 41.5 years with 70.0% being females. 64.1% of participants had a confirmed diagnosis of migraine. Out of which, 56.8% were not being treated by a physician despite 74.0% having migraine disability assessment (MIDAS) grade 2. At the end of six months, participants reported 54.0% decrease in migraine-related disability and a 9.0% increase in the patient activation measure (PAM), a measure which assesses patient knowledge, skill, and confidence for self-management. Loss of productivity through both, absenteism and presenteism, were reduced by more than 50.0% and in addition participants report their private life being significantly less impaired by migraine.

Novartis is exploring opportunities to work with other employers who are interested in supporting their employees and family members living with migraine.

About Migraine

Migraine is a distinct neurological disease1. It involves recurrent attacks of moderate to severe head pain that is typically pulsating, often unilateral and associated with nausea, vomiting and sensitivity to light, sound and odors2. Migraine is associated with personal pain, disability and reduced quality of life, and financial cost to society3. It has a profound and limiting impact on an individual's abilities to carry out everyday tasks; the World Health Organization reported migraine to be one of the top 10 causes of years lived with disability for men and women4. It remains under-recognized and under-treated3,5.

Disclaimer

This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as potential, can, will, plan, may, could, would, expect, anticipate, seek, look forward, believe, committed, investigational, pipeline, launch, or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AGs current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.

About Novartis

Novartis is reimagining medicine to improve and extend peoples lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the worlds top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 145 nationalities work at Novartis around the world. Find out more athttps://www.novartis.com.

View post:
Novartis study reveals that migraine support in the workspace can significantly decrease the impact of the disease on affected employees -...

May is American Stroke Month; Baystate Health neurologist says know the signs for this brain attack – masslive.com

SPRINGFIELD Dr. Rajiv Padmanabhan doesnt need a calendar to remind him that May is American Stroke Month.

However, the Baystate Medical Center neurologist notes that many people remain unaware of the symptoms of stroke and the importance of getting immediate medical attention to avoid disability and even death.

He adds that the coronavirus pandemic further underscores the importance of calling 9-1-1 when this cerebrovascular accident that impacts blood and oxygen flow to the brain is suspected.

Though not common, Padmanabhan said stroke can be a complication in severe cases of COVID-19, the disease caused by the new coronavirus.

He adds anyone experiencing a life-threatening event like a stroke should not let fear of exposure to COVID-19 prevent them from seeking immediate medical care. He said Baystate is among those in the medical community that has taken extensive steps" to reduce such exposure.

It is very important not to delay care in stroke as the outcome can be worse. It is very important now more than ever to call 9-1-1 right away, Padmanabhan said.

It is important to know that time is brain. The phrase time is brain emphasizes that human nervous tissue is rapidly lost as stroke progresses and emergent evaluation and therapy are required.

Sometimes referred to as a brain attack," a stroke is caused by blockage of blood flow or bleeding into the brain and its symptoms include numbness, confusion and severe headache.

A ruptured brain aneurysm a weakened area of a blood vessel that begins to bleed can also cause stroke.

Interruption in the flow of blood, which carries oxygen and other nutrients to the brain, can cause cells to die and impair function. The act F.A.S.T. evaluation helps with awareness of stroke and the need for quick treatment.

A healthy lifestyle can help reduce stroke risk and other preventative measures include discussions with a medical provider about maintaining the desired blood pressure and whether there is a family history for cardiovascular disease.

Padmanabhan was asked to explain further about stroke, which is the leading cause of disability among adults and one of the top causes of death in the United States.

Q. A stroke can be quite disabling. Why is that?

A. The part of the brain that controls that part of body is unique in its purpose and function and, usually after a stroke, that part of the brain ceases to function resulting in loss of that modality. That being said, each part of brain works in unison with other areas and stroke in one area can affect the connections other parts of the brain rely on.

Thus, strokes can be disabling not only in the loss of function but also by the way of the downstream effects.

Q. What is the difference between ischemic and hemorrhagic stroke?

A. A hemorrhagic stroke is due to rupture in an artery due to weakening of the arterial wall. This results in blood seeping into the brain affecting that part of the body where the bleed occurred.

An ischemic stroke is a clotting type of stroke that occurs when a clot forms within an artery due to plaque, that is, hardening of artery, or due to a clot arising from elsewhere. A clotting stroke and a bleeding stroke affect the body similarly and so to tell the difference urgent scans are needed and treatments change according to the type of stroke.

Q. The death rate from stroke has dropped considerably since the drug tPA, tissue plasminogen activator, was approved by the FDA in the 1990s to treat acute ischemic stroke. How does it work and how are patients evaluated for this treatment?

A. TPA breaks up the clot in a clogged artery in an ischemic stroke and tries to restore flow back to brain. This reduces the number of nerve cells, that is, neurons, to survive, improving the chances of good outcome or recovery and minimizing the severity and consequently decreasing complications from a severe stroke, including death.

Q. Thrombectomy therapy can also be used to treat acute ischemic stroke. Would you explain this and when is it applicable and is it used in combination with tPA?

A. Thrombectomy is most useful when we can actually see a large clot in the artery that can be removed by the way of a catheter device that is threaded up an artery in the groin under anesthesia.

This offers the best hope for patients who otherwise would have worse outcomes. It can be done in some cases until 24 hours of stroke. To identify and treat as quickly as possible, we incorporate scans looking not only at the brain but also the arteries that go the brain in a very rapid manner so we can effectuate treatment much faster.

Q. What success has Baystate seen in treating acute ischemic stroke patients with this therapy?

A. We have had tremendous success in the approaches we have taken both by decreasing the time to treatment by the way of clot busting treatment but also having the ability to quickly get the patient to the catheter lab to remove the clot and restore blood flow in a timely manner.

This has led to more discharges to home rather than to nursing home.

Q. How is hemorrhagic stroke treated?

A. We usually control the blood pressure to minimize further damage to the brain, and in addition if the patient is on a blood thinner, we have medications to reverse the effects of blood thinner as well.

Q. What are some of the cardiovascular risks for stroke that people should be aware and possibly address to avoid stroke?

There are modifiable risk factors: such as hypertension, that is, high blood pressure, diabetes, smoking, sedentary lifestyle, obesity, high cholesterol.

There is also a correlation with sleep apnea.

Atrial fibrillation can pose a risk for clotting stroke.

Cutting salt, exercising more and checking your numbers with your primary care doctor is important.

Q. How are health care providers better managing these risks in their patients?

A. Primary care providers are on the frontline of these risk factor assessments and management.

It is very important to follow up with your primary care doctor and the ask the question: what are my risk factors, and what are my numbers?

It is also important to tell your primary care doctor of any medical conditions that run in the family, and that may increase the risk for stroke and heart attack.

Q. Signs of stroke can differ by gender. Would you explain?

A. In the Atherosclerosis Risk in Communities Study it was found that men were more likely to experience walking issues with stroke compared to women.

The National Institutes of Health recommends improved education for women and their caregivers to seek care early, especially with mild symptoms, and not wait to call 9-1-1.

Q. Most strokes occur in people over 65, but it is estimated that about 10 percent of strokes occur in those 45 and younger in the U.S. What are some of the causes of this, and is vaping considered a potential risk factor?

A. Stroke in age less than 45, often described as stroke in young, may not only be due to traditional risk factors. There can be additional factors for example, certain rare clotting disorders, tear in the arteries, and due to effects of vaping, smoking and illicit drugs.

One study found vaping increasing the stroke risk by three-fold compared to those who did not.

Adding cigarette smoking to vaping can further increase stroke risk by another two-fold.

Q. What success has Baystate seen in terms of lower morbidity and mortality rates around strokes in the last decade with improved treatment and awareness?

A. There has been a significant improvement in not only the deaths, but also disability following the implementation of specialized stroke systems of care in the last 10 years, thus cutting treatment times, significant improvement in window for treatment of thrombectomy for clot removal especially over the last several years.

Q. Are most of your patients aware of the signs of stroke and the importance of calling 9-1-1 quickly?

A. Many of the patients are not aware of all the stroke signs and symptoms. And in one survey many of the patients did not know their risk factors and importance of controlling them after a stroke had already occurred.

It is important for family and caregivers to be aware of stroke symptoms to be able to act quickly by calling 9-1-1.

Q. What is the No. 1 thing you would like people to know in terms of lowering their risk for stroke?

A. It is important to see your primary care doctor and make sure you ask the risk questions. Majority of strokes are preventable.

Q. Is it too late for older people, especially those with underlying conditions, to reduce their risk for stroke?

A. Not at all, older patients may have several underlying conditions, but with the help of their primary care doctor, it is possible to have a tailored approach to management of risk factors.

Additionally, with the new blood thinners we prescribe for atrial fibrillation to prevent the bleeding, complications have decreased over the years; it is important to know to ask about the newer agents when you visit your doctor.

Q. What more do you want younger people to know in terms of preventing their risk for stroke as they age?

A. It is good to have a healthy routine of diet and exercise and to continue to follow up with your primary care doctor. If you are smoking then quitting smoking now can be very important in preventing stroke and heart problems.

Q. Do brain aneurysms affect stroke risk?

A. Yes, a ruptured brain aneurysm can cause stroke in a manner different from the traditional stroke and can occur in the first 14 to 21 days of aneurysm bleed.

To help prevent and manage such complications we have dedicated staff and protocols in the neurointensive care unit at Baystate.

If an aneurysm is found incidentally and has not ruptured, we do have neurointervenitional clinic expertise that your doctor can refer to to help address this by the way of catheter-guided coiling of the aneurysm to prevent a bleeding from occurring in the first place.

Excerpt from:
May is American Stroke Month; Baystate Health neurologist says know the signs for this brain attack - masslive.com

Europe, the rare neurological disease treatment market, is anticipated to reach US$ 3,763.41 Mn in 2027 from US$ 2,048.10 Mn in 2019 – GlobeNewswire

New York, May 21, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Europe Rare Neurological Disease Treatment Market to 2027 - Regional Analysis and Forecasts by Indication ; Drug Type ; Distribution Channel ; Mode of Administration and Country" - https://www.reportlinker.com/p05894548/?utm_source=GNW Restraining factors, such as higher cost of rare neurological disease treatments likely to damage the growth of the market in the coming years.

On the other hand, artificial intelligence for the treatment of rare neurological diseases is expected to have a positive impact on the growth of the Europe rare neurological disease treatment market in the coming years. A large group of rare diseases that have inefficient diagnoses and treatments are the neurological disease.These diseases target the nervous system, which include the brain, spinal cord, and all the nerves that run throughout the human body.

There is no surety regarding the onset of the diseases; some can strike during childhood, whereas others can affect even highly aged people. In the world of medicine, rare neurological diseases represent significant burden on health systems in terms of disease diagnosis, treatment, and management.Some of the majorly observed rare neurological diseases comprises narcolepsy, amyotrophic lateral sclerosis, Alzheimers disease, multiple sclerosis, spinal muscular atrophy (SMA), Duchenne muscular dystrophy, and others.

According to a data published by World Health Organisation (WHO), it is estimated that about 30 million Europeans in 27 EU-countries suffer from a rare disease. Over the past few decades, various research and developmental works have been carried out pertaining to the diagnosis and management of rare neurological diseases.Advancements in healthcare systems and modernizing diagnostic systems are likely to enhance the screening operation for rare neurological diseases.

Additionally, increasing prevalence of rare neurological diseases is expected to drive the growth of the rare neurological disease treatment market during the forecast period. In 2019, the Alzheimers disease accounted for the largest market share in the Europe rare neurological disease treatment market.Alzheimers disease is a progressive disease and a type of dementia, and the condition is characterized by eating and death of brain cells.

It is characterized by symptoms such as reduced thinking, memory loss, and lacking behavioural sense.These symptoms get worse over time and highly reduce the independently for daily routine.

The disease accounts for nearly 60% to 80% of all dementia cases.It is widely seen among the aging population.

In Germany, more than 1.5 million people are living with Alzheimers disease. For instance, In 2012, Alzheimers Europe reports that 1,572,104 individuals with dementia were in Germany. This constitutes 1.92 per cent of the total 81,990,837 population. The number of people with dementia is marginally higher than the EU average of 1.55 per cent. In 2019, the biologics segment, held the most significant market share of the rare neurological disease treatment market by the drug type.This segment is also anticipated to be the fastest growing segment of the market in 2027, owing to the increasing neurological disorders, coupled with increasing robust hospital infrastructure and advancements in medicines, has enabled people for various treatments for the deadliest diseases.

Hence, the segment is anticipated to witness growth at a significant rate during the forecast period. Some of the significant primary and secondary sources for cold plasma equipment included in the report are World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA) and National Institute of Health (NIH)Read the full report: https://www.reportlinker.com/p05894548/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

View post:
Europe, the rare neurological disease treatment market, is anticipated to reach US$ 3,763.41 Mn in 2027 from US$ 2,048.10 Mn in 2019 - GlobeNewswire

Early consultation with a neurologist can go a long way in mitigating the effects of Parkinsons disease – Express Healthcare

Dr (Lt Gen) CS Narayanan, HOD, Department of Neurology, Manipal Hospitals, Dwarka discusses how Parkinsons disease varies from person to person and how it can be managed with proper medication and following a healthy lifestyle

Early consultation with a neurologist can go a long way in mitigating the effects of Parkinsons disease which is a chronic neurological illness caused by damage to brain cells that produce a chemical messenger called dopamine. Early detection and timely medical intervention are the keys to the effective management of the disease.

The effects and severity of Parkinsons disease vary person to person from various advanced age groups and for those, who led a very active disease or distress free so far, it comes as trauma. When Parkinsons hit persons may develop an unfamiliar pain and stiffness in the right shoulder and notice that they are taking longer than usual to shave, wear their clothes and get ready for work. Over time they may develop a tremor in their hands. It is evident that a general sense of fatigue overpowers the patients.

Sometimes people feel depressed also. These are clear signs and symptoms of Parkinsons and at this point in time, people should consult a neurologist for the management of the disease as there is no cure for it as such.

The neurologists normally see all the symptoms and decide about the stage. After a thorough examination, experts point out whether it is an early-stage case or a severe one. While there are no conclusive tests, we need to depend on the combination of symptoms and findings on physical examination.

Combating Parkinsons is not difficult and patients, with proper consultation, come to terms with it. Taking prescribed medicine regularly along with a regimen of exercise and also modified lifestyle help a lot in managing the disease.

While Parkinsons disease is more common in those who are above 50 years of age, it can also sometimes affect younger persons. It may also be inherited sometimes. Typically people with Parkinsons disease experience tremor, slowness of movements, limb rigidity, along with gait and balance problems. These are called motor symptoms. Patients may also have several non-motor symptoms such as mood disorders, difficulty in planning and organising, sleep difficulty, constipation, lack of ability to smell, and sexual dysfunction. The severity of symptoms and pace of progression of symptoms often varies from one person to another.

A combination of medications, some designed to replenish the amount of dopamine in the brain and others to arrest the progression of the disease are often prescribed. They are very effective in the early stages but the neurologist may adjust the doses and introduce new drugs as the disease progresses. If the medications become less effective over time or if side-effects become bothersome, advanced approaches to management such as deep brain stimulation (DBS) and surgery are considered. With DBS, electrodes are surgically implanted in the brain. They send electrical impulses to stimulate the parts of the brain that control movement. Evidence suggests that patients with Parkinsons disease also benefit from a multidisciplinary approach to care.

Parkinsons disease can be managed with proper attention and medical consultation. It is proven that early consultation and close interaction with a neurologist thereafter can go a long way in mitigating the effects of Parkinsons disease. By knowing the nature of the disease and the various effective ways of managing it, patients with Parkinsons disease can pursue their work, hobbies, and go on to lead a life full of joy.

View post:
Early consultation with a neurologist can go a long way in mitigating the effects of Parkinsons disease - Express Healthcare

Chronic Kidney Disease is Associated With Intracranial Atherosclerotic Disease – Neurology Advisor

Chronic kidney disease (CKD), defined as either a reduced kidney function based on estimated glomerular filtration rate (eGFR) and cystatin C (CysC) or the presence of kidney damage, is associated with an increased risk for intracranial atherosclerotic disease (ICAD), according to study results published in Neurology.

Previous studies have reported an increased risk for cardiovascular morbidity and mortality among patients with CKD, but limited data are available on the association between CKD and ICAD and whether the association between CKD and extracranial atherosclerosis can be generalized to intracranial arteries. The goal of the current study was to explore the association between reduced kidney function and kidney damage with ICAD.

The researchers used data from the Atherosclerosis Risk in Communities (ARIC) study and included data on kidney function measurements and 3-dimensional vessel wall MRI. This technique is able to characterize intracranial plaques as well as the severity of stenosis and serves as an effective tool for assessing ICAD.

The associations between kidney measures and ICAD status were analyzed in binomial (presence vs absence of ICAD, presence vs absence of detectable stenosis) and multinomial (0 vs 1 and 0 vs 2 plaques, absent or mild stenosis vs 50%70% and >70% stenosis or occlusion). The main outcomes were presence of intracranial plaques and luminal stenosis.

The analysis included 1762 participants (mean age 76.3 years, 41.5% men) who received MRI scans with good vessel wall image quality and with available kidney measures. Most patients (63.7%) did not have a plaque on vessel wall MRI; 293 (16.6%) had 1 plaque; and 347 (19.7%) had multiple (2) plaques. Among 640 participants with at least 1 plaque, 189 (29.5%) had 1 plaque causing 50% stenosis, and 944 (14.7%) had 1 plaque causing >70% stenosis or occlusion.

A total of 51.7% of participants with plaques and 42.2% of those without plaques had eGFR based on CysC (eGFRcysc) <60 mL/min/1.73 m2. The risk for ICAD was significantly increased for patients with reduced kidney function, compared to those with normal kidney function (adjusted odds ratio [aOR] 1.29; 95% CI, 1.04-1.60). Furthermore, eGFRcysc <60 mL/min/1.73 m2 was associated with presence of any detectable stenosis (aOR 1.31; 95% CI 1.04-1.63) and with the presence of >70% stenosis or occlusion independently (OR 2.15; 95% CI 1.32-3.50) but not with lesser degrees of stenosis.

In adjusted multinomial logistic regression models, eGFRcysc <60 mL/min/1.73 m2 was associated with a 41% increased risk for having a single plaque (aOR 1.41; 95% CI, 1.06-1.87), compared to no plaque, but there was no significantly increased risk for multiple plaques.

While elevated albumin-to-creatinine ratio (ACR) or CysC did not show significant associations with plaque presence when assessed as continuous variables, in multinomial logistic regression models, albuminuria was associated with presence of 50% to 70% stenosis with an adjusted OR of 2.01 (95% CI 1.143.55) for ACR 30 (vs <30) and 2.88 (95% CI 1.038.10) for ACR 300 (vs <300). CysC was associated with presence of >70% stenosis or occlusion independently (aOR 3.16; 95% CI 1.446.94).

The study had several limitations, according to the researchers, including the cross-sectional design, inclusion of relatively healthy, and small number of subjects with significant stenosis.

Our study revealed that CKD is associated with ICAD in a subset of participants in the ARIC cohort. Thus, kidney disease should be considered an important factor in risk stratification for cerebrovascular disease, concluded the researchers.

Reference

Hao Q, Gottesman RF, Qiao Y, et al. Association between kidney disease measures and intracranial atherosclerosis: The ARIC study [published online ahead of print, 2020 Apr 17]. Neurology. doi:10.1212/WNL.0000000000009311

Read more here:
Chronic Kidney Disease is Associated With Intracranial Atherosclerotic Disease - Neurology Advisor

Epilepsy and COVID-19: Connection and Considerations – Neurology Advisor

The effect of epilepsy on coronavirus disease 2019 (COVID-19), and vice versa, have been little explored. In a brief communication published in Epilepsy and Behavior, Naoto Kuroda, MD, from Wayne State University, provided information about the associations between, and the considerations for, COVID-19 and epilepsy.

While associations between COVID-19 and epilepsy have not been reported, the Centers for Disease Control and Prevention indicate that epilepsy, among other neurological comorbidities, may be a risk factor for the disease. This is in direct contrast to current medical knowledge and literature, all of which lack data to support an association between epilepsy and a higher risk of COVID-19. However, patients with epilepsy who smoke or have diabetes, cancer, lung disease, or obesity may be at an increased risk.

In addition, the effects of COVID-19 on epilepsy are unclear. It is likely that COVID-19 may cause fever in patients with epilepsy, and this fever may in turn trigger seizures. Symptoms of COVID-19, which are primarily respiratory and gastrointestinal in nature, have not shown any impact on seizure related symptoms in patients with epilepsy.

Future treatment of COVID-19 may impact epilepsy, particularly in terms of drug-drug interactions. Drugs that are being considered for COVID-19 treatment must be considered in relation to how they may interact with anti-epileptic drugs (AEDs). Currently, levetiracetam is of interest for patients with epilepsy as it does not appear to interact with any potential COVID-19 medication.

While some epilepsy medications may affect the immune system (eg, steroids), Dr Kuroda suggests that there is evidence that treatments like everolimus have the potential to prevent viral infections. As such, he emphasizes the need to choose epilepsy medications on an individual basis. In patients with well-controlled seizures, discontinuing or changing AEDs for the purpose of preventing infection is not recommended.

Dr Kuroda also noted that elective surgeries for patients with epilepsy should be postponed to prevent the spread of COVID-19. Urgent interventions should be performed under strict prevention and protection protocols. Healthcare providers and other medical professionals are encouraged to provide this information to patients with epilepsy to help curb anxiety and potentially reduce seizure frequency.

Reference

Kuroda N. Epilepsy and COVID-19: Associations and important considerations. Epilepsy Behav. 2020;108:107122. doi: 10.1016/j.yebeh.2020.107122.

View post:
Epilepsy and COVID-19: Connection and Considerations - Neurology Advisor

Global Neurology Software Market Register a xx% CAGR in Terms of Revenue By 2025: Epic, Athenahealth, Nextgen, healthfusion, Allscripts, Greenway…

A research report on the Global Neurology Software Market offers a detailed analysis about the market share, size, trends, and growth prospects. In addition, the report contains market volume with an accurate estimation offered in the report. The data offered in this report is gathered based on the latest industry news, trends, as well as opportunities. Moreover, the report comprises a complete market analysis and provider landscape with the help of SWOT analysis of the major service providers. This research report provides an extensive evaluation of the Neurology Software Market. The Global Neurology Software Market report is designed through the detailed qualitative insights, verifiable projections, and historical data about the Neurology Software Market size.

This study covers following key players:

EpicAthenahealthNextgenhealthfusionAllscriptsGreenway HealthPractice FusionBrainlabKareoBizmaticsAdvanced Data SystemsNueMD

Request a sample of this report @ https://www.orbismarketreports.com/sample-request/98665?utm_source=Pooja

In addition, the projections offered in this report have been derived with the help of proven research assumptions as well as methodologies. By doing so, the Neurology Software research study offers collection of information and analysis for each facet of the Neurology Software Market such as technology, regional markets, applications, and types. Likewise, the Neurology Software Market report offers some presentations and illustrations about the market that comprises pie charts, graphs, and charts which presents the percentage of the various strategies implemented by the service providers in the Global Neurology Software Market. In addition to this, the report has been designed through the complete surveys, primary research interviews, as well as observations, and secondary research.

Access Complete Report @ https://www.orbismarketreports.com/global-neurology-software-market-growth-analysis-by-trends-and-forecast-2019-2025?utm_source=Pooja

Market segment by Type, the product can be split into

Type IType II

Market segment by Application, split into

HospitalsCollege & Research InstitutesOther

Moreover, the Neurology Software Market report introduced the market through several factors such as classifications, definitions, market overview, product specifications, cost structures, manufacturing processes, raw materials, and applications. It also includes the major market conditions across the globe such as the product profit, price, production, capacity, demand, supply, as well as market growth structure. In addition, this report offers significant data through the SWOT analysis, investment return data, and investment feasibility analysis. The Neurology Software Market study also sheds light on the highly lucrative market opportunities that influences the growth of the global market. Moreover, the study offers a complete analysis of the market size, segmentation, and market share. Additionally, the Neurology Software report contains market dynamics such as market restraints, growth drivers, opportunities, service providers, stakeholders, investors, key market players, profile assessment, and challenges of the global market.

Some Major TOC Points:1 Report Overview2 Global Growth Trends3 Market Share by Key Players4 Breakdown Data by Type and ApplicationContinued

For Enquiry before buying report @ https://www.orbismarketreports.com/enquiry-before-buying/98665?utm_source=Pooja

About Us : With unfailing market gauging skills, has been excelling in curating tailored business intelligence data across industry verticals. Constantly thriving to expand our skill development, our strength lies in dedicated intellectuals with dynamic problem solving intent, ever willing to mold boundaries to scale heights in market interpretation.

Contact Us : Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155

Go here to read the rest:
Global Neurology Software Market Register a xx% CAGR in Terms of Revenue By 2025: Epic, Athenahealth, Nextgen, healthfusion, Allscripts, Greenway...

COVID-19 and the Rise of Telemedicine for Chronic Neurological Disorders – Neurology Advisor

The coronavirus disease 2019 (COVID-19) outbreak has brought telemedicine into a new light with a rapid increase in the use of telemedicine and a recent viewpoint published in JAMA Neurology focused on the remote care of patients with chronic neurological disorders.

Bastiaan R. Bloem, MD, PhD, medical director of the Department of Neurology at Radboud University Medical Center, Nijmegen, the Netherlands explained that in light of the strong recommendation to avoid outpatient visits if possible, there has been a growing understanding that chronic neurological care can be safely delivered remotely and may be best delivered as close to the patients home as possible.

Episodic outpatient visit often provide an unrealistic perspective of the patients status and are not a reliable tool to identify rare complications or assess treatment outcomes that can fluctuate over time. On the other hand, home visits provide confidentiality, have the advantage of assessing the patients natural environment and can prevent the risks associated with long travels to the hospitals.

Telemedicine approaches can include videoconferencing for remote consultations, as well as remote monitoring using sensors that can be passive (occurring in the background) or active (asking patients to completed scheduled tasks).

Despite the potential advantages of telemedicine, it was not successful as anticipated with many stating that making a change in healthcare is a challenging task. However, the current COVID-19 global crisis has accelerated the use of telemedicine and remote consultation is becoming an increasingly attractive option across many healthcare systems. The experience of many patients and families has also been positive.

While previously there were many concerns regarding the use of telemedicine, the current crisis and the rise in telemedicine has helped to overcome many of the earlier objections against its use as it was shown that a simple neurological assessment can be performed remotely, the success was not limited to young patients but was also shown in many older adults, and reimbursement mechanisms were successfully implemented.

However, there are also challenges associated with this rapid rise in telemedicine, such as issues regarding privacy, security and participants confidentiality.

Telemedicine for chronic neurological disorders should become part of the new normal rather than the exception. Governments, health care systems, and payers should be encouraged to continue to embrace the new age of access from home, even after the pandemic passes, concluded Bloem.

Reference

Bloem BR, Dorsey ER, Okun MS. The Coronavirus disease 2019 crisis as catalyst for telemedicine for chronic neurological disorders [published online ahead of print, 2020 Apr 24]. JAMA Neurol. doi:10.1001/jamaneurol.2020.1452

View post:
COVID-19 and the Rise of Telemedicine for Chronic Neurological Disorders - Neurology Advisor

Branching Out in the Area of Genetic Neurology: Collaborating with Australian Clinical Trial Experts, Upcoming Webinar Hosted by Xtalks – PR Web

TORONTO (PRWEB) May 04, 2020

In this webinar, attendees will learn about the growing field of genetic neurology, with a focus on therapeutic discoveries, innovations in Phase I trials and leveraging the expertise of Australian-based experts and clinical trial providers.

Inspired by breakthroughs in the genetics of epilepsy, Massachusetts-based Praxis Precision Medicines is focused on both rare genetic epilepsies and more common central nervous system (CNS) disorders. To bring their innovations through the first phase of discovery and validation, Praxis sought the expertise of Australias largest Phase 1 clinical provider, Nucleus Network.

The discovery of gene variants that cause epilepsy has been led by a group of world-class academic researchers in Melbourne, Australia. It was this hotbed of epilepsy and genetics leaders that first attracted Praxis to Melbourne. However, when the company began to explore where to conduct their initial Phase 1 studies, they were grateful to find Nucleus Network in the same city, with just the right expertise and capabilities. Moreover, with a population of over 5 million, Melbourne has been an ideal location for Praxis studies. According to Praxis Senior Medical Director, Dr. Gabi Belfort, Nucleus Network offered an excellent solution for even highly technical studies involving the monitoring of brain waves by electroencephalography (EEG).

One critical study that was conducted at Nucleus involved measuring the pharmacodynamic effect (on EEG) of one of Praxis lead molecules in a multiple ascending dose study. The data collected in this study facilitated dose selection for a subsequent trial in patients with a psychiatric disease. Following on from the success of these initial trials, Praxis will be undertaking a titration study with Nucleus Network for another therapeutic, which may be useful for treating epilepsy or movement disorders.

Join Cameron Johnson, CEO, Nucleus Network and Gabi Belfort, MD, PhD, Senior Medical Director, Praxis Precision Medicines in a live webinar on Tuesday, May 19, 2020 at 4pm EST.

For more information or to register for this event, visit Branching Out in the Area of Genetic Neurology: Collaborating with Australian Clinical Trial Experts.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.comFor information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

See the original post here:
Branching Out in the Area of Genetic Neurology: Collaborating with Australian Clinical Trial Experts, Upcoming Webinar Hosted by Xtalks - PR Web

Rashes, headaches, tingling: the less common coronavirus symptoms that patients have – The Guardian

The World Health Organization lists the most common symptoms of Covid-19 as fever, tiredness and a dry cough. Others include a runny nose, sore throat, nasal congestion, pain, diarrhoea and the loss of sense of taste and/or smell. But there are also other more unusual symptoms that patients have presented.

Patients in several countries have reported rashes on their toes, resembling chilblains, in many cases unaccompanied by any of the usual symptoms of the virus. The condition has been dubbed Covid toe. The rashes can take the form of red or purple lesions and, despite the name, can be found on the side or sole of the foot, or even on hands and fingers. The European Journal of Pediatric Dermatology reported an epidemic of cases among children and adolescents in Italy. It said that unlike other rashes associated with coronavirus, it had not been previously observed.

Conjunctivitis has been a rare symptom in cases of Covid-19, with viral particles being found in tears. In the UK, the Royal College of Ophthalmologists and College of Optometrists says: It is recognised that any upper respiratory tract infection may result in viral conjunctivitis as a secondary complication, and this is also the case with Covid-19. However, it is unlikely that a person would present with viral conjunctivitis secondary to Covid-19 without other symptoms of fever or a continuous cough as conjunctivitis seems to be a late feature where is has occurred.

A peer-reviewed Spanish study, published in the British Journal of Dermatology last week, found that 6% of the 375 coronavirus cases examined involved livedo, the death of body tissue due to a lack of blood supply, or livedo, discolouration of the skin. The skin can become mottled and have purple or red patchy areas, which may appear in a lace-like pattern. In the study, it was generally found in older patients with more severe cases of Covid-19. However, this was not consistent across the board and necrosis was also found in some people with coronavirus who did not require hospitalisation.

A study of 214 patients in China, published in Jama Neurology last month, found that just over a third (36.4%) had experienced neurological symptoms such as dizziness or headaches, increasing to 45.5% in those with severe coronavirus infections. Commenting on the research, Prof Ian Jones, professor of virology at the University of Reading, said: It happens, but is generally not what coronaviruses do. At the moment neurological complications might best be considered a consequence of Covid-19 disease severity rather than a distinct new concern.

Some patients have complained about a tingling, fizzing or even burning sensation. Dr Waleed Javaid, the director of infection prevention and control at Mount Sinai hospital in New York, told Today.com it was likely the patients immune response to Covid-19 rather than the virus itself was causing such sensations. He said: Theres a widespread immune response that is happening. Our immune cells get activated so a lot of chemicals get released throughout our body and that can present or feel like theres some fizzing. When our immune response is acting up, people can feel different sensations I have heard of similar experiences in the past with other illnesses.

More here:
Rashes, headaches, tingling: the less common coronavirus symptoms that patients have - The Guardian

ORYZON First Quarter 2020 Results and Corporate Update Madrid Stock Exchange:ORY.MC – GlobeNewswire

MADRID, Spain and CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the first quarter of 2020 and provided an update on recent developments.

Dr Carlos Buesa, Oryzons Chief Executive Officer, said, "Oryzon continued to advance its clinical programs in the first quarter. We are encouraged by the exciting signals of clinical efficacy observed in both our iadademstat oncology and vafidemstat neurology programs, combined with good safety and tolerability profiles.

During the last weeks of Q1 and into Q2 2020, the Covid-19 pandemic has impacted activities of pharma and biotech companies globally. As the company reported in an ad-hoc note released on April 17th, Oryzon has not canceled or postponed recruitment in ongoing clinical trials, however clinical operations have been adapted to protect the health of patients, their families and healthcare professionals, and to preserve the integrity of the trial data as much as possible. Also as previously disclosed, Oryzon is postponing the initiation of its vafidemstat Phase IIb trial in agitation-aggression in patients with borderline personality disorder (PORTICO trial) until lock-down conditions are eased sufficiently. To contribute to the global fight against the pandemic, Oryzon launched a Phase II clinical trial, named ESCAPE, in severe Covid-19 patients to prevent acute respiratory distress syndrome (ARDS). The trial was approved by the Spanish Drug Agency via an accelerated procedure as reported in an ad-hoc note released on April 24th.

First Quarter and Recent Highlights

Iadademstat in oncology:

Vafidemstat in neurological disease:

Financial Update: First Quarter 2020 Financial Results

Research and development (R&D) expenses were $4.3 million for the last 3 months ended March 31, 2020 compared to $2.6 million for the last 3 months ended March 31, 2019. The $1.7 million increase was driven primarily by expenses associated with advancing the companys clinical trials.

General and administrative expenses were $0.9 million for the last 3 months ended March 31, 2020 and for 3 months ended March 2019.

Net loss was $1.1 million for the last 3 months ended March 31, 2020, compared to net loss of $1.0 million for the last 3 months ended March 2019.

Cash, cash equivalents and marketable securities totaled $32.3 million as of March 31, 2020, compared to $32.7 million as of March 31, 2019.

About OryzonFounded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. Oryzon has one of the strongest portfolios in the field. Oryzons LSD1 program has rendered two compounds, vafidemstat and iadademstat, in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurological diseases. Oryzon has offices in Spain and the United States. For more information, visit http://www.oryzon.com

FORWARD-LOOKING STATEMENTS This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words expects, anticipates, believes, intends, estimates and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisin Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forwardlooking statements, whether as a result of new information, future events or otherwise. This press release is not an offer of securities for sale in the United States or any other jurisdiction. Oryzons securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of Oryzons securities to be made in the United States will be made by means of a prospectus that may be obtained from Oryzon or the selling security holder, as applicable, that will contain detailed information about Oryzon and management, as well as financial statements.

Read the original here:
ORYZON First Quarter 2020 Results and Corporate Update Madrid Stock Exchange:ORY.MC - GlobeNewswire

PEDIATRIC NEUROLOGY DEVICE Market: A Deep Dive Analysis of Various Regions and Strategies During Forecast Period 2020 2025 : lana , Inova Healthcare…

PEDIATRIC NEUROLOGY DEVICE Market 2020 Updated for the impact of COVID-19Chicago, United States,- Report Hive Research announces the release of the report PEDIATRIC NEUROLOGY DEVICE Market Research Report by Top Keyplayers, by Type, by Application, Global Forecast to 2025 Cumulative Impact of COVID-19

Latest update onPEDIATRIC NEUROLOGY DEVICE MarketAnalysis report published with extensive market research, PEDIATRIC NEUROLOGY DEVICE Market growth analysis, and forecast by 2025. This report is highly predictive as it holds the overall market analysis of topmost companies into the PEDIATRIC NEUROLOGY DEVICE industry. With the classified PEDIATRIC NEUROLOGY DEVICE market research based on various growing regions, this report provides leading players portfolio along with sales, growth, market share, and so on.

The report highlights several significant features of the global PEDIATRIC NEUROLOGY DEVICE market encompassing competitive landscape, segmentation analysis, and industry environment. It shows the scope of the market and a brief overview of the definition and description of the product or service. The potential factors that can bring the market to the upward direction have been mentioned in the report. With this report, companies, as well as individuals interested in this report, will get proven valuable guidelines and direction so that they consolidate their position in the market. The report assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the PEDIATRIC NEUROLOGY DEVICE industry. Growth of the overall PEDIATRIC NEUROLOGY DEVICE market has also been forecasted for the period 2020-2025, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

PEDIATRIC NEUROLOGY DEVICE Market competition by top Manufacturers:<>

lana, Inova Healthcare System, Medtronic, The Nemours Foundation, Stryker, Boston Scientific, B.Braun Melsungen, Integra LifeSciences, St. Jude Medical

>>>>To know How COVID-19 Pandemic Will Impact This PEDIATRIC NEUROLOGY DEVICE Market| Download PDF Sample copy of the Report

The report provides insights on the following pointers:

NOTE: Our team is studying Covid-19 impact analysis on various industry verticals and Country Level impact for a better analysis of markets and industries. The 2020 latest edition of this report is entitled to provide additional commentary on latest scenario, economic slowdown and COVID-19 impact on overall industry. Further it will also provide qualitative information about when industry could come back on track and what possible measures industry players are taking to deal with current situation.

PEDIATRIC NEUROLOGY DEVICE Market Report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including PEDIATRIC NEUROLOGY DEVICE market size, volume and value, as well as price data.

This study analysis was given on a worldwide scale, for instance, present and historical PEDIATRIC NEUROLOGY DEVICE growth analysis, competitive analysis, and also the growth prospects of the major regions. The report gives an exhaustive investigation of this market at country & regional levels, and provides an analysis of the industry trends in each of the sub-segments, from production, revenue and consumption. A quantitative and qualitative analysis of the main players in related regions is introduced, from the perspective of PEDIATRIC NEUROLOGY DEVICE production, PEDIATRIC NEUROLOGY DEVICE revenue, PEDIATRIC NEUROLOGY DEVICE consumption and PEDIATRIC NEUROLOGY DEVICE price.

According to the current situation, the official counts of cases and deaths from COVID-19 have passed 4,000,000 and 280,000 at the time of this report. Many government announced a plan on reopening the national economy, but many countries are still at the stage of rising. XYZResearch published a report for global PEDIATRIC NEUROLOGY DEVICE market in this environment.

In terms of revenue, this research report indicated that the global PEDIATRIC NEUROLOGY DEVICE market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of PEDIATRIC NEUROLOGY DEVICE industry comprises of Asia, North America, South America, Middle East and Africa, Europe, with the production and revenue data in each of the sub-segments.The lana aims at producing XX PEDIATRIC NEUROLOGY DEVICE in 2020, with XX % production to take place in global market, Inova Healthcare System accounts for a volume share of XX %.

At the upcoming analysis, this report discusses industrial policy, economic environment, in addition to the COVID-19 impact and cost structures of the industry. And this report encompasses the fundamental dynamics of the market which include drivers, opportunities, and challenges faced by the industry. Additionally, this report showed a keen market study of the main consumers, raw material manufacturers and distributors, etc.

PEDIATRIC NEUROLOGY DEVICE Market Classification by Types:

Neurosurgery DevicesNeurostimulatorCerebrospinal Fluid (CSF) Management Devices

PEDIATRIC NEUROLOGY DEVICE Market Size by End-user Application:

HospitalsHealthcare CentersNeurological Research Centers

Regional Analysis:The report comprises of regional development status, covering all the major regions of the world. This regional status shows the size (in terms of value and volume), and price data for the global PEDIATRIC NEUROLOGY DEVICE market. The development of the industry is assessed with information on the current status of the industry in various regions. Data type assessed concerning various regions includes capacity, production, market share, price, revenue, cost, gross, gross margin, growth rate, consumption, import, export, etc.

Regional coverage:North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Some Main Reasons For Purchasing This Report:

Readers of this report will receive in-depth knowledge about the market.

Updated statistics offered on the global PEDIATRIC NEUROLOGY DEVICE market report.

This report provides an insight into the market that will help you boost your companys business and sales activities.

It will help you to find prospective partners and suppliers.

It will assist and strengthen your companys decision-making processes.

The research report of the PEDIATRIC NEUROLOGY DEVICE market is predicted to accrue a significant remuneration portfolio by the end of the predicted time period. It includes parameters with respect to the PEDIATRIC NEUROLOGY DEVICE market dynamics incorporating varied driving forces affecting the commercialization graph of this business vertical and risks prevailing in the sphere. In addition, it also speaks about the PEDIATRIC NEUROLOGY DEVICE Market growth opportunities in the industry.

Major Highlights from Table of contents are listed below for quick lookup into PEDIATRIC NEUROLOGY DEVICE Market report

In this report, Leading players of the global PEDIATRIC NEUROLOGY DEVICE Market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global PEDIATRIC NEUROLOGY DEVICE Market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global PEDIATRIC NEUROLOGY DEVICE Market. It also provides useful recommendations for new as well as established players of the global PEDIATRIC NEUROLOGY DEVICE Market.

Why Go For Report Hive Research?

Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Get in Touch with Us :Report Hive Research500, North Michigan Avenue,Suite 6014,Chicago, IL 60611,United StatesWebsite: : https://www.reporthive.comEmail: [emailprotected]Phone:+1 312-604-7084

Go here to read the rest:
PEDIATRIC NEUROLOGY DEVICE Market: A Deep Dive Analysis of Various Regions and Strategies During Forecast Period 2020 2025 : lana , Inova Healthcare...

Neurologist talks about risk of blood clots, stroke, and heart attack associated with COVID-19 – fox8.com

Free download: How to talk to your kids about wearing a maskNews / 6 hours ago

One of our Gender Reveal families welcomes a girl!Syndication / 8 hours ago

AJ Petitti explains what you should be doing right now to get your garden ready to plantNews / 8 hours ago

Neurologist talks about risk of blood clots, stroke, and heart attack associated with COVID-19News / 9 hours ago

Tri-C teacher dresses in costumes to keep students engagedNews / 1 day ago

Local teachers make video to inspire and motivate students through online learningNews / 1 day ago

Doctor on reopening Ohio: 'This is not a return to business as usual'News / 1 day ago

Stork Report 4.22.20Syndication / 2 days ago

Cleveland's Own Allie LaForce and husband feed healthcare workers through #ProjectFrontlineNews / 4 days ago

'Be kind to one another': Cleveland Clinic nurse shares message with Northeast Ohio from New York CityNews / 4 days ago

'What I've seen is teamwork':Cleveland Clinic doctor talks about the people on the frontlines of coronavirus pandemicNews / 4 days ago

Helping those battling alcoholism during the coronavirus outbreakNews / 5 days ago

Read more:
Neurologist talks about risk of blood clots, stroke, and heart attack associated with COVID-19 - fox8.com

Effects of Hypertension on Cognitive Function Following Stroke – Neurology Advisor

While stroke survivors with higher systolic blood pressure (SBP) and diastolic blood pressure (DBP) measurements are more likely to have worse cognitive performance at 90 days, this association is most likely mediated by sociodemographic and clinical factors, according to study results published in the Journal of Stroke and Cerebrovascular Diseases.

Cognitive decline is commonly seen following stroke and was previously found to be associated with increased disability and mortality. While high blood pressure is associated with late-life cognitive impairment, there are no clear data on the association between blood pressure levels and poststroke cognitive decline. The goal of the current study was to investigate the associations between SBP, DBP, and antihypertensive medication use with cognitive function at 90 days after stroke.

The researchers used data from the Brain Attack Surveillance in Corpus Christi (BASIC) project, a population-based stroke surveillance project in Nueces County, Texas. All participants were required to have measurements of blood pressure and cognitive function at the 90-day in-person outcome assessment.

The study sample included 432 participants aged 45 years (median age 66 years, 45% female), most of them were diagnosed with an ischemic stroke and the median National Institutes of Health stroke score was 3.

The primary outcome was the modified Mini-Mental Status Examination (3MSE) and secondary outcomes included the Animal Fluency Test (AFT) to assess executive function and Trail Making Tests A and B divided by completion time to assess visuomotor tracking, information processing speed, divided attention, and cognitive flexibility.

While higher SBP and lower DBP each were significantly associated with lower 3MSE scores, following multiple adjustments for patient factors both did not remain independently associated with 3MSE. Similarly, higher SBP and lower DBP each were significantly associated with worse cognitive performance for AFT, Trails A, and Trails B, but these associations disappeared following adjustment for clinical factors, other than the association between DBP with worse Trails B scores.

Lower cognitive performance was associated with older age, less education, Mexican American ethnicity, diabetes, higher stroke severity, more depressive symptoms, and lower BMI.

Most stroke survivors with hypertension were adherent to anti-hypertensive medication (71%). While there was no association between nonadherence to antihypertensive medication with 3MSE scores, among hypertensive stroke survivors, nonadherence was associated with lower AFT scores, compared to those who adhered to the prescribed medication (adjusted difference, -1.21 points; 95% CI, -2.24 to -0.19; P=.02), but not other tests.

The study had several limitations, according to the researchers, including the cross-sectional design, relatively small sample size, exclusion of a large number of stroke patients due to missing data, limited data on stroke and structural brain features, measurement of blood pressure and assessment of the cognitive outcomes only at 90 days after stroke with no available data on the cognitive function at other time points.

Stroke survivors [blood pressure] levels were not associated with cognitive performance at 90 days independent of sociodemographic and clinical factors, conclude the researchers.

Reference

Levine DA, Galecki AT, Okullo D, et al. Association of blood pressure and cognition after stroke [published online May 1, 2020]. J Stroke Cerebrovasc Dis. doi:10.1016/j.jstrokecerebrovasdis.2020.104754

See the original post:
Effects of Hypertension on Cognitive Function Following Stroke - Neurology Advisor

Artax Biopharma Announces the Formation of Scientific Advisory Board to Advance Autoimmune Disease Therapy AX-158 – BioSpace

CAMBRIDGE, Mass., June 24, 2020 /PRNewswire/ --Artax Biopharma, Inc., a biotechnology company focused on transforming autoimmune disease treatment, today announces the formation of their Scientific Advisory Board (SAB). The SAB is comprised of experts in Immunology, Autoimmune Disease, and T Cell Signaling, and was formed to guide the company as it proceeds into future clinical trials with a first-in-class, oral small molecule autoimmune disease immunomodulator AX-158.

Artax Biopharma is poised to enter clinical trials with the small molecule AX- 158, a novel approach to treat multiple autoimmune diseases without causing the immunosuppression commonly associated with current autoimmune disease therapies.

Balbino Alarcn, PhD, Chairman of Artax's Scientific Advisory Board, commented, "I am privileged to lead Artax's Scientific Advisory Board, which mobilizes global leaders in Immunology, Autoimmune Disease, and T Cell Signaling. Collectively we are enthusiastic to collaborate on, and contribute to, important development initiatives related to Artax's innovative approach to autoimmune disease treatment."

"Artax Biopharma's Nck inhibitor AX-158 has shown impressive experimental biologic and mechanistic impact on T cell modulation - managing autoimmune disease without inducing the profound immunosuppression or interference with memory response associated with conventional or biological therapies," stated Dr. Lawrence Steinman, Stanford University Zimmerman Professor of Neurology and Neurosciences, Pediatrics, and Genetics and Scientific Advisory Board member.

"Convening a Scientific Advisory Board is a critical step as we accelerate our clinical development program," stated Artax Biopharma Chief Executive Officer Joseph Lobacki. "The clinical expertise and knowledge of these experts is unparalleled and will be instrumental in informing our development strategy across several autoimmune diseases."

The SAB will be comprised of five experts, and is being led by Professor Balbino Alarcn, PhD, co-founder of Artax Biopharma:

Balbino Alarcn, PhDDr. Alarcn is Program Director at the National Research Council of Spain (CSIC) and Head of the TCR-mediated Signal Transduction Laboratory.

Raif Geha, MDDr. Geha is the James L. Gamble Professor of Pediatrics at Harvard Medical School and Chief of the Allergy/Immunology/Rheumatology and Dermatology Division at Children's Hospital in Boston.

Menno de Rie, MDProf. de Rie is a board-certified dermatologist and vice-chair of the department of Dermatology of the Amsterdam University Medical Centres/ University of Amsterdam.

Lawrence Steinman, MDDr. Steinman is the George A. Zimmermann professor of Neurology and Neurological Sciences, Pediatrics, and Genetics at Stanford University.

Cox Terhorst, PhDDr. Terhorst is Chief of Immunology at Beth Israel Deaconess Medical Center and Professor at Harvard Medical School.

About ImmunomodulationA healthy immune system eliminates harmful foreign pathogens, while being tolerant of self-tissues and organs. When the immune system malfunctions, cells (T Cells) attack self-tissues and organs, causing autoimmune disease. Current autoimmune disease therapies suppress the immune system, helping to minimize these self-attacks, but also raise susceptibility to harmful foreign pathogens. Immunomodulation, the process in which the immune system reduces self-attacks while properly reacting to fight foreign pathogens, holds great potential for autoimmune disease.

About Artax-158AX-158 is a first-in-class, oral small molecule, preclinical immunomodulating agent in development for the treatment of autoimmune diseases. AX-158 employs a novel mechanism of action that selectively modulates, or adjusts, T cell responses that play a critical role in immune system function. By selectively inhibiting Nck, a protein, AX-158 selectively modulates self-directed T Cell activation which is a cause of autoimmune disease. Importantly, data suggest AX-158 is not immunosuppressive and does not impact the immune system's ability to mount a strong response to foreign pathogens and infections. Further, AX-158's ability to modulate T cell responses allows the possibility to broadly target several autoimmune diseases, therefore potentially transforming autoimmune disease treatment.

About Artax BiopharmaArtax Biopharma is a biotechnology company transforming autoimmune disease treatment. Artax is a life science industry leader in autoimmune disease immunomodulation science, developing an innovative small molecule approach to treat autoimmune disease that modulates the immune system to both treat autoimmune disease and allow the body to fight foreign pathogens. The company is examining a first-in-class oral immunomodulating agent as a new way to treat multiple autoimmune diseases without causing the immune suppression commonly associated with currently available autoimmune disease therapies. For more information, please visit http://www.artaxbiopharma.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/artax-biopharma-announces-the-formation-of-scientific-advisory-board-to-advance-autoimmune-disease-therapy-ax-158-301082763.html

SOURCE Artax Biopharma

Read more from the original source:
Artax Biopharma Announces the Formation of Scientific Advisory Board to Advance Autoimmune Disease Therapy AX-158 - BioSpace

Eisai will shift U.S. HQ to New Jersey ‘bio-ecosystem’ in move to boost oncology, neurology portfolios – FiercePharma

Japanese drugmaker Eisai has established asolid foothold in the U.S. market and found some success with its Merck & Co.-partnered oncology med Lenvima. And alongside BIogen, it's in the FDA queue for a landmark decision in Alzheimer's disease.

But Eisai'sstateside ambitions are broader than thatand as if to illustrate that point, the company is plotting a new U.S. headquarters on a high-tech New Jersey campus.

Eisai will relocateits U.S. headquarters from Woodcliff Lake, New Jersey, to a 15-story complex at the ON3 "bio-ecosystem" in Nutley, New Jersey, by the end of 2021,the Tokyo-based drugmaker said Tuesday.

Accelerate Clinical Operations Across Sponsors, CROs, and Partners

The most advanced life sciences organizations know that digital innovation and multi-platform integrations are essential for enabling product development. New platforms are providing the life sciences industry with an opportunity to improve the efficiency of clinical trials and reduce costs while remaining compliant and reducing risk.

Eisai will be the first biopharma tenant at the 116-acre site,formerly Roche'sU.S. headquarters, alongside residents from the healthcare, R&D and diagnostics fields. All told, Eisai will ship 1,200 of its corporate and R&D employees to the site, which the drugmaker called "technologically advanced and cutting edge."

The move will give Eisai the opportunity to collaborate outside biopharma to boost its oncology, Alzheimer's disease and neurological portfolios, the company said. The location in a brand-new hub will also help Eisai recruit talented employees, a spokesperson said.

Eisai's relocation comes as the Japanese drugmaker works to boost its top-sellingoncology med Lenvima, which has found a promising partnership with Merck's Keytrudaalong with its share of setbacks.

Meanwhile, the drugmaker is also working with partner Biogen on controversial Alzheimer's drug aducanumab, which the FDA accepted for priority review last week.The agency expects to decide the fate of the treatment by March 7.

RELATED:Merck, Eisai's Keytruda-Lenvima combo stonewalled in liver cancer after Roche's first-in-class green light

That was a big loss for the duo, which still has just one FDA approval to its credit inendometrial carcinoma.The partners hoped an approval would put themup againstRoches pairing of immuno-oncology agent Tecentriq and anti-VEGF drug Avastin, which recently scoredan FDA nod in first-line liver cancer with gold-standard data showing they could help patients live longer.

The two companies are stilltesting the Keytruda-Lenvima combo as a first-line liver cancer therapy in the phase 3 Leap-002 study, which isfully enrolled.

RELATED:Eisai preps for launch with insomnia med Dayvigo after buying out Purdue

Meanwhile, Eisai has worked to flesh out its neurology business, scoring an FDA approval in December for Dayvigo, an insomnia castoff from Purdue Pharma.

Eisai took full ownership of Dayvigoin May 2019 after itbought outPurdue's stake in the drug in 2015.The drug is an orexin receptor antagonist that works by targeting the wake center of the brain, according to EisaiCEO and president of itsglobal neurology businessIvan Cheung, who called the approval "very exciting" at the time.

Read more from the original source:
Eisai will shift U.S. HQ to New Jersey 'bio-ecosystem' in move to boost oncology, neurology portfolios - FiercePharma